In 2011, the Myanmar National Malaria Control Programme (NMCP) introduced PQ to the National Antimalaria Treatment Policy, which recommended that a 3-day chloroquine together with a 14-day PQ (0.25 mg/kg/day) be given to patients with P. vivax malaria by BHS without glucose 6 phosphate dehydrogenase (G6PD) testing. The gene discussed is G6PD; the disease is malaria.